MUC5B and interstitial lung disease: Building on this finding, a Finnish study, by combining large-scale genotype data with clinical data from a national healthcare registry, found that among RA patients, the lifetime risk of developing ILD was 16.8% for MUC5B carriers and 6.1% for MUC5B non-carriers (Palomaki et al., 2021).